WO2020136671A1 - Improved process for the preparation of lapatinib base and it's anhydrous ditosylate salt - Google Patents

Improved process for the preparation of lapatinib base and it's anhydrous ditosylate salt Download PDF

Info

Publication number
WO2020136671A1
WO2020136671A1 PCT/IN2019/050930 IN2019050930W WO2020136671A1 WO 2020136671 A1 WO2020136671 A1 WO 2020136671A1 IN 2019050930 W IN2019050930 W IN 2019050930W WO 2020136671 A1 WO2020136671 A1 WO 2020136671A1
Authority
WO
WIPO (PCT)
Prior art keywords
formula
lapatinib
anhydrous
base
aqueous
Prior art date
Application number
PCT/IN2019/050930
Other languages
French (fr)
Inventor
Shankar Reddy BUDIDETI
Srinivasan ABAYEE KALIYAPERUMAL
Srinivasa Krishna Murthy Konduri
Jayakrishna KASUGANTI
Nagalingam SAMATHAM
Vijaya Lakshmi CHAPALA
Pulla Reddy Muddasani
Venkaiah Chowdary Nannapaneni
Original Assignee
Natco Pharma Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Natco Pharma Limited filed Critical Natco Pharma Limited
Publication of WO2020136671A1 publication Critical patent/WO2020136671A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Definitions

  • the present invention relates to an improved, high yielding and industrially viable process for the preparation of highly pure Lapatinib and its anhydrous ditosylate salt.
  • the present invention can be easily adopted for scale-up studies.
  • Lapatinib is a 4-anilinoquinazoline kinase inhibitor.
  • Lapatinib ditosylate is /V-[3-ch loro-4-[(3-fluorophenyl)methoxy] phenyl )-6-[5-[(2- methylsulfonylethylamino)methyl)-2-furanyl] -4-quinazolinamine, ditosylate of formula ( 1 ) as depicted below.
  • Lapatinib of formula (2) is marketed as Lapatinib ditosylate monohydrate of formula (6) under the brand name TYKERB ® .
  • Lapatinib used as an orally active drug for breast cancer and other solid tumors. It is a dual tyrosine kinase inhibitor which intermpts the HER2/neu and epidermal growth factor receptor (EGFR) pathways. It is used in combination therapy for HER2-positivebreast cancer.
  • Lapatinib of formula (2) The process for the preparation of Lapatinib of formula (2), is first disclosed in US6727256 (scheme-1). According to this process, the aldehyde of formula (3) on reaction with 2-methanesulfonylethylamine of formula (4) in the presence of catalytic amount of glacial acetic acid in dichloromethane medium, followed by reduction in the presence of sodium triacetoxyborohydride (NaBH(OAc)3) affords Lapatinib of formula (2) as an organic residue, which is further purified by column chromatography.
  • NaBH(OAc)3 sodium triacetoxyborohydride
  • Lapatinib ditosylate anhydrate is purified via Lapatinib ditosylate monohydrate of formula (6) by crystallization from ⁇ 20% aqueous tetrahydrofuran followed by trituration in methanol for 4 days to afford Lapatinib ditosylate anhydrous of formula (1).
  • the disclosed process has following drawbacks.
  • Tosylate salt of aldehyde may not give any additional advantage for the imine formation reaction. Moreover, p-toluenesulfonic acid is removed as organic waste.
  • aldehyde of formula (3) is condensed with 2-(methylsulfone)ethylamine hydrochloride of formula (7) in the presence of triethylamine in methanol medium at reflux temperature to afford imine intermediate of formula (8).
  • imine intermediate of formula (8) is reduced in the presence of sodium borohydride in methanol medium at 10-15°C to afford Lapatinib base of formula (2) in crude form which is further purified from methanol to afford pure Lapatinib base of formula (2).
  • Lapatinib base of formula (2) is converted to Lapatinib ditosylate salt of formula (1) using para toluenesulfonic acid monohydrate in methanol medium to afford pure Lapatinib ditosylate of formula (1).
  • the main objective of the present invention is to provide an improved process for the preparation of compound of formula (1) as shown in scheme- 4, which comprises simple, economical, high yielding and commercially viable process which surpasses the above mentioned limitations, thereby imine formation under homogeneous conditions in the presence of base which could avoid the reversible reaction thereby controlling the unwanted impurities.
  • sodium triacetoxyborohydride with stabilized aqueous sodium borohydride solution for the reduction of imine of formula (8) under homogeneous conditions in organic solvent mixture medium in this manner increase the overall yield and quality of Lapatinib base of formula (2).
  • another main objective of the present invention is to provide an improved process for the preparation of compound of formula (1), which comprises Lapatinib ditosylate salt formation in aqueous tetrahydrofuran medium. Accordingly, one more main objective of the present invention is to provide an improved process for the preparation of compound of formula (1), which comprises isolation of Lapatinib tosylate in anhydrous form by simple trituration from tetrahydrofuran.
  • One aspect of the present invention is to provide a process for the preparation of Lapatinib ditosylate anhydrous of formula (1),
  • Lapatinib base of formula (2) is purified by crystallization / trituration in an organic solvent medium to afford pure Lapatinib base of formula (2),
  • Lapatinib ditosylate anhydrous of formula (1) is purified in tetrahydrofuran to afford pharmaceutically pure Lapatinib ditosylate anhydrous of formula (1).
  • One embodiment of the present invention is to provide a process for the preparation of Lapatinib ditosylate anhydrous of compound of formula (1), comprising the steps of: (i) condensing aldehyde of formula (3) with 2-(Methylsulfonyl)ethylamine hydrochloride of formula (7) in the presence of an organic base in organic solvent medium to afford compound of formula (8) which in-turn subjected to reduction with stabilized aqueous reducing agent solution in organic solvent mixture medium to afford Lapatinib base of formula (2),
  • Lapatinib base of formula (2) is purified by crystallization / trituration in an organic solvent medium to afford pure Lapatinib base of formula (2),
  • Lapatinib ditosylate anhydrous of formula (1) is purified from an organic solvent medium to afford pharmaceutically pure Lapatinib ditosylate anhydrous formula (1).
  • step (i) the organic base used for condensation of aldehyde of formula-(3) with 2- (Methylsulfonyl)ethylamine hydrochloride of formula (7) is triethylamine.
  • step (i) the organic solvent used during condensation of aldehyde of formula (3) with 2-(Methylsulfonyl)ethylamine Hydrochloride of formula (7) is dichloromethane.
  • step (i) the temperature at which condensation of aldehyde of formula (3) with 2- (Methylsulfonyl)ethylamine Hydrochloride of formula (7) is selected from 0-40°C preferably at 25-30°C.
  • step (i) Imine of formula (8) is reduced in the presence of stabilized aqueous sodium borohydride solution.
  • the organic solvent mixture medium used for reduction of imine of formula (8) is selected from dichloromethane, methanol, isopropyl alcohol, ethanol or mixture thereof preferably in dichloromethane-methanol mixture.
  • step (i) the temperature at which reduction of imine of formula (8) in the presence of aqueous sodium borohydride in dichloromethane-methanol mixture is selected from 0-40°C, preferably, at 5-20°C.
  • step (i) Lapatinib base of formula (2) is optionally purified by crystallization / trituration in an organic solvent medium in isopropyl alcohol, ethanol, methanol, ethylacetate, tetrahydrofuran or any other suitable organic solvent medium preferably isopropyl alcohol.
  • the solvent medium used for the conversion of Lapatinib base of formula (2) to its Lapatinib ditosylate of formula (1) by treating it with para toluenesulfonic acid monohydrate is selected from water, aqueous tetrahydrofuran, aqueous isopropyl alcohol, aqueous methanol, aqueous ethanol, aqueous tertiary butanol, or mixture thereof preferably aqueous tetrahydrofuran.
  • step (ii) Lapatinib ditosylate of formula (1) is isolated in anhydrous form in tetrahydrofuran.
  • the process of the present invention discloses direct isolation of Lapatinib ditosylate in anhydrous form.
  • Lapatinib ditosylate anhydrous of formula (1) from the present invention has having HPLC purity more than 99.5%.
  • N-(3-chloro-4-(3-fluorobenzyloxy)anilino)-6- quinazolinyl)-furan-2-carbaldehyde(4) is prepared according to prior art process.
  • N-(3-chloro-4-(3-fluorobenzyloxy)anilino)-6-quinazolinyl)-furan-2-carbaldehyde (4) (lOOg; 0.211 mole) was reacted with 2-methanesulfonylethylamine HC1 (7) (47.2g; 0.295 mole) in the presence of triethylamine (42.7g; 0.421 mole) in dichloromethane at 25-30°C under N2 atmosphere and monitored progress of the reaction by HPLC. After completion of reaction, methanol followed by cold aqueous stabilized sodiumborohydride solution (20.0g; 0.527 mole) were added, maintained at 10-15°C and monitored progress of the reaction by HPLC.
  • Example-2 Lapatinib ditosylate anhydrous (1)
  • Lapatinib base 75g; 0.129 mole
  • p-TSA 54g; 0.283 mole
  • aqueous THF 150 mL
  • the resulting solution was treated with carbon activated, filtered and washed.
  • the filtrate was cooled to 0-5°C, maintained for 3-4h, filtered the product, washed and dried at 75-80°C under vacuum to obtain pure Lapatinib ditosylate anhydrous product (110.5g; 92.5%)

Abstract

The present invention relates to an improved, high yielding and industrially viable process for the preparation of high pure Lapatinib of formula (1). The present invention involves simple crystallization techniques avoiding column chromatographic techniques and the process conditions can be easily adopted for scale-up studies.

Description

IMPROVED PROCESS FOR THE PREPARATION OF LAPATINIB BASE
AND IT’S ANHYDROUS DITOSYLATE SALT
Field of the invention:
The present invention relates to an improved, high yielding and industrially viable process for the preparation of highly pure Lapatinib and its anhydrous ditosylate salt. The present invention can be easily adopted for scale-up studies.
Background of the Invention:
Lapatinib is a 4-anilinoquinazoline kinase inhibitor. The chemical name of
Lapatinib ditosylate is /V-[3-ch loro-4-[(3-fluorophenyl)methoxy] phenyl )-6-[5-[(2- methylsulfonylethylamino)methyl)-2-furanyl] -4-quinazolinamine, ditosylate of formula ( 1 ) as depicted below.
Figure imgf000002_0001
Lapatinib of formula (2) is marketed as Lapatinib ditosylate monohydrate of formula (6) under the brand name TYKERB®. Lapatinib used as an orally active drug for breast cancer and other solid tumors. It is a dual tyrosine kinase inhibitor which intermpts the HER2/neu and epidermal growth factor receptor (EGFR) pathways. It is used in combination therapy for HER2-positivebreast cancer.
The process for the preparation of Lapatinib of formula (2), is first disclosed in US6727256 (scheme-1). According to this process, the aldehyde of formula (3) on reaction with 2-methanesulfonylethylamine of formula (4) in the presence of catalytic amount of glacial acetic acid in dichloromethane medium, followed by reduction in the presence of sodium triacetoxyborohydride (NaBH(OAc)3) affords Lapatinib of formula (2) as an organic residue, which is further purified by column chromatography.
Figure imgf000003_0001
Scheme-1
The disclosed process could be more efficient and commercially viable, if the following disadvantages are avoided.
a) Condensation of aldehyde of formula (3) with amine of formula (4) under acidic condition may lead to reversible reaction and form aldehyde of formula (3) which also can undergo reduction with sodium triacetoxyborohydride resulting unwanted impurities.
b) Usage of expensive and highly unstable reducing agent like sodium triacetoxyborohydride .
c) Commercially impracticable column chromatography as Lapatinib is a large volume product.
d) Huge volumes of organic solvents, energy and time consuming while doing column purification.
In another patent, US7157466, process for the preparation of ditosylate salts of Lapatinib of formula (1) as shown in Scheme-2. According to this patent, tosylate salt of aldehyde of formula (5) is reacted with 2-(methylsulfone)ethylamine of formula (4) in tetrahydrofuran in the presence of diisopropylethylamine (DIPEA) and the resulting solution is subjected to reduction in the presence of sodium triacetoxyborohydride (NaBH(OAc)3) at room temperature. Later the reaction mixture is basified to pH 10-11 using addition of 5N sodium hydroxide and the resulting organic layer is treated with para toluenesulfonic acid monohydrate (/7-TSA.H2O) to afford Lapatinib ditosylate anhydrous. Thereafter Lapatinib ditosylate anhydrate is purified via Lapatinib ditosylate monohydrate of formula (6) by crystallization from ~ 20% aqueous tetrahydrofuran followed by trituration in methanol for 4 days to afford Lapatinib ditosylate anhydrous of formula (1).
Figure imgf000004_0001
The disclosed process has following drawbacks.
a) Usage of expensive and unstable reducing agent like sodium triace toxyborohydride .
b) Tosylate salt of aldehyde may not give any additional advantage for the imine formation reaction. Moreover, p-toluenesulfonic acid is removed as organic waste.
c) Prolonged trituration (for four days) in methanol to afford Lapatinib ditosylate anhydrous of formula (1) is a time taking process.
In another patent, US8664389, as depicted in scheme-3, aldehyde of formula (3) is condensed with 2-(methylsulfone)ethylamine hydrochloride of formula (7) in the presence of triethylamine in methanol medium at reflux temperature to afford imine intermediate of formula (8). Later imine intermediate of formula (8) is reduced in the presence of sodium borohydride in methanol medium at 10-15°C to afford Lapatinib base of formula (2) in crude form which is further purified from methanol to afford pure Lapatinib base of formula (2). Thereafter, Lapatinib base of formula (2) is converted to Lapatinib ditosylate salt of formula (1) using para toluenesulfonic acid monohydrate in methanol medium to afford pure Lapatinib ditosylate of formula (1).
Figure imgf000005_0001
Scheme-3
In spite of having prior art methods for the preparation of compound of formula (1), there is a need to have simple, cost effective, high yielding and commercially viable process for the preparation of Lapatinib ditosylate anhydrous of formula (1) on large scale operations since, the above shortcomings may affect the commercial production of Lapatinib ditosylate anhydrous of formula ( 1 ).
Object of the present invention:
Accordingly, commercially viable process is developed by addressing the below drawbacks like:
a) Avoid highly unstable and expensive reducing agent, sodium triacetoxyborohydride (NaBH(OAc)3) for the reduction process. b) To overcome the non-homogeneous mixture during reduction of imine of formula (8).
c) Avoid additional purification of Lapatinib base of formula (2)
d) Avoid column purification in the process.
e) Avoid prolonged cycle time.
f) Incorporate appropriate process controls.
g) Avoid tosylate salt of aldehyde of formula (5) in the process which may affect the atom economy.
h) Improve the overall yield of Lapatinib ditosylate anhydrous of formula ( 1 )
Keeping in view of the above drawbacks associated with the prior art processes disclosed for the preparation of Lapatinib ditosylate anhydrous of formula (1), the inventors of the present invention have developed a simple, economical, high yielding and commercially viable process for commercial production of Lapatinib ditosylate anhydrous of formula (1) by modifying the process.
Accordingly, the main objective of the present invention is to provide an improved process for the preparation of compound of formula (1) as shown in scheme- 4, which comprises simple, economical, high yielding and commercially viable process which surpasses the above mentioned limitations, thereby imine formation under homogeneous conditions in the presence of base which could avoid the reversible reaction thereby controlling the unwanted impurities. Apart from that, replacing expensive and unstable reducing agent, sodium triacetoxyborohydride with stabilized aqueous sodium borohydride solution for the reduction of imine of formula (8) under homogeneous conditions in organic solvent mixture medium, in this manner increase the overall yield and quality of Lapatinib base of formula (2).
Accordingly, another main objective of the present invention is to provide an improved process for the preparation of compound of formula (1), which comprises Lapatinib ditosylate salt formation in aqueous tetrahydrofuran medium. Accordingly, one more main objective of the present invention is to provide an improved process for the preparation of compound of formula (1), which comprises isolation of Lapatinib tosylate in anhydrous form by simple trituration from tetrahydrofuran.
Figure imgf000007_0001
Scheme-4
Summary of the present invention:
One aspect of the present invention is to provide a process for the preparation of Lapatinib ditosylate anhydrous of formula (1),
Figure imgf000007_0002
comprising the steps of:
(i) condensing aldehyde of formula (3)
Figure imgf000008_0003
with 2-(Methylsulfonyl)ethylamine hydrochloride of formula (7)
Formula (7)
Figure imgf000008_0001
in the presence of an organic base in organic solvent medium to afford imine of formula
(8),
Figure imgf000008_0002
which in-turn subjected to reduction with stabilized aqueous reducing agent solution in organic solvent mixture medium to afford Lapatinib base of formula (2),
Figure imgf000008_0004
Optionally Lapatinib base of formula (2) is purified by crystallization / trituration in an organic solvent medium to afford pure Lapatinib base of formula (2),
(ii) reacting Lapatinib base of formula-(2) with para toluenesulfonic acid monohydrate in aqueous-tetrahydrofuran to obtain anhydrous Lapatinib ditosylate,
Figure imgf000009_0002
optionally Lapatinib ditosylate anhydrous of formula (1) is purified in tetrahydrofuran to afford pharmaceutically pure Lapatinib ditosylate anhydrous of formula (1).
Figure imgf000009_0001
Detailed Description of the Present Invention:
One embodiment of the present invention is to provide a process for the preparation of Lapatinib ditosylate anhydrous of compound of formula (1), comprising the steps of: (i) condensing aldehyde of formula (3) with 2-(Methylsulfonyl)ethylamine hydrochloride of formula (7) in the presence of an organic base in organic solvent medium to afford compound of formula (8) which in-turn subjected to reduction with stabilized aqueous reducing agent solution in organic solvent mixture medium to afford Lapatinib base of formula (2),
optionally Lapatinib base of formula (2) is purified by crystallization / trituration in an organic solvent medium to afford pure Lapatinib base of formula (2),
(ii) reacting Lapatinib base of formula-(2) with para toluenesulfonic acid monohydrate in aqueous-tetrahydrofuran to obtain anhydrous Lapatinib ditosylate(l),
optionally Lapatinib ditosylate anhydrous of formula (1) is purified from an organic solvent medium to afford pharmaceutically pure Lapatinib ditosylate anhydrous formula (1).
In step (i), the organic base used for condensation of aldehyde of formula-(3) with 2- (Methylsulfonyl)ethylamine hydrochloride of formula (7) is triethylamine.
In step (i), the organic solvent used during condensation of aldehyde of formula (3) with 2-(Methylsulfonyl)ethylamine Hydrochloride of formula (7) is dichloromethane. In step (i), the temperature at which condensation of aldehyde of formula (3) with 2- (Methylsulfonyl)ethylamine Hydrochloride of formula (7) is selected from 0-40°C preferably at 25-30°C.
In step (i), Imine of formula (8) is reduced in the presence of stabilized aqueous sodium borohydride solution.
In step (i), the organic solvent mixture medium used for reduction of imine of formula (8) is selected from dichloromethane, methanol, isopropyl alcohol, ethanol or mixture thereof preferably in dichloromethane-methanol mixture.
In step (i), the temperature at which reduction of imine of formula (8) in the presence of aqueous sodium borohydride in dichloromethane-methanol mixture is selected from 0-40°C, preferably, at 5-20°C. In step (i), Lapatinib base of formula (2) is optionally purified by crystallization / trituration in an organic solvent medium in isopropyl alcohol, ethanol, methanol, ethylacetate, tetrahydrofuran or any other suitable organic solvent medium preferably isopropyl alcohol.
In step (ii), the solvent medium used for the conversion of Lapatinib base of formula (2) to its Lapatinib ditosylate of formula (1) by treating it with para toluenesulfonic acid monohydrate is selected from water, aqueous tetrahydrofuran, aqueous isopropyl alcohol, aqueous methanol, aqueous ethanol, aqueous tertiary butanol, or mixture thereof preferably aqueous tetrahydrofuran.
In step (ii), Lapatinib ditosylate of formula (1) is isolated in anhydrous form in tetrahydrofuran.
Advantages of the Present Invention:
(i) As the imine of formula (8) is in homogeneous solution under basic conditions, the possibility of reversible reaction is minimized which avoid formation of unwanted impurities.
(ii) The process of the present invention requires commercially viable stabilized aqueous sodium borohydride solution as reducing agent.
(iii) The process of the present invention discloses direct isolation of Lapatinib ditosylate in anhydrous form.
(iv) The purity of the isolated Lapatinib base of formula (2) is -99% which is sufficient to convert to its pharmaceutical grade ditosylate salt of Lapatinib of formula (1) in anhydrous form.
(v) The process of the present invention successfully avoids chromatographic purification technique from the process.
(vi) Lapatinib ditosylate anhydrous of formula (1) from the present invention has having HPLC purity more than 99.5%.
(vii) The process of the present invention is commercially viable and industrially applicable and cost effective. (viii) The overall yield of Lapatinib ditosylate anhydrous of formula (1) is >89% from aldehyde of formula (3).
According to the Present invention, N-(3-chloro-4-(3-fluorobenzyloxy)anilino)-6- quinazolinyl)-furan-2-carbaldehyde(4) is prepared according to prior art process.
The Present invention is further illustrated in detail with reference to following examples. It is desired that the examples be considered in all respect as illustrative and are not intended to limit the scope of the invention in any way. Example-1: Preparation of Lapatinib base (2):
N-(3-chloro-4-(3-fluorobenzyloxy)anilino)-6-quinazolinyl)-furan-2-carbaldehyde (4) (lOOg; 0.211 mole) was reacted with 2-methanesulfonylethylamine HC1 (7) (47.2g; 0.295 mole) in the presence of triethylamine (42.7g; 0.421 mole) in dichloromethane at 25-30°C under N2 atmosphere and monitored progress of the reaction by HPLC. After completion of reaction, methanol followed by cold aqueous stabilized sodiumborohydride solution (20.0g; 0.527 mole) were added, maintained at 10-15°C and monitored progress of the reaction by HPLC. The reaction mass was treated with DM water and aqueous sodium hydroxide, separated the organic layer and concentrated. The concentrated mass was treated with IPA at reflux temperature, filtered, washed with IPA and dried at 60-65°C to obtain pure Lapatinib base (118.9g; 97%); HPLC: -99%
Example-2: Lapatinib ditosylate anhydrous (1)
To the solution of Lapatinib base (75g; 0.129 mole) in aqueous THF (2.25L), p-TSA (54g; 0.283 mole) dissolved in aqueous THF (150 mL) was added at ambient temperature, heated to 57.5±2.5°C. The resulting solution was treated with carbon activated, filtered and washed. The filtrate was cooled to 0-5°C, maintained for 3-4h, filtered the product, washed and dried at 75-80°C under vacuum to obtain pure Lapatinib ditosylate anhydrous product (110.5g; 92.5%)
HPLC purity: >99.5%

Claims

We Claim:
1. A process for the preparation of compound of formula (1),
Figure imgf000013_0002
comprising the steps of
(i) condensing aldehyde of formula (3)
Figure imgf000013_0003
with 2-(Methylsulfonyl)ethylamine hydrochloride of formula (7)
Formula (7)
Figure imgf000013_0001
in the presence of an organic base in organic solvent medium to afford compound of formula (8),
Figure imgf000014_0001
which in-turn subjected to reduction with stabilized aqueous reducing agent solution in organic solvent mixture medium to afford Lapatinib base of formula (2),
Figure imgf000014_0002
Optionally Lapatinib base of formula (2) is purified by crystallization / trituration in an organic solvent medium to afford pure Lapatinib base of formula (2),
(ii) reacting Lapatinib base of formula-(2) with para toluenesulfonic acid monohydrate in aqueous-tetrahydrofuran to obtain anhydrous Lapatinib ditosylate,
Figure imgf000015_0001
optionally Lapatinib ditosylate anhydrous of formula (1) is purified in an organic solvent medium to afford pharmaceutically pure Lapatinib ditosylate anhydrous of formula ( 1 ).
2. The process according to claim 1, wherein in step (i), aldehyde of formula-(3) is condensed with 2-(Methylsulfonyl)ethylamine Hydrochloride of formula (7) in the presence of triethylamine in dichlorome thane.
3. The process according to claim 1 and 2, wherein in step (i), imine of formula (8) is reduced in the presence of aqueous stabilized sodium borohydride solution.
4. The process according to claim 1, wherein in step (i), the organic solvent mixture medium used for reduction of imine of formula (8) is selected from dichlorome thane, methanol, isopropyl alcohol, ethanol or mixture thereof.
5. The process according to claim 1 , wherein the solvent used for purification in step (i), Lapatinib base of formula (2) is selected from isopropyl alcohol, ethanol, methanol, ethylacetate, tetrahydrofuran.
6. The process according to claim 1, wherein in step (ii), solvent medium used in the preparation of Lapatinib ditosylate of formula (1) is selected from water, aqueous tetrahydrofuran, aqueous isopropyl alcohol, aqueous methanol, aqueous ethanol, aqueous tertiary butanol, or mixture thereof.
7. The process according to claim 1, wherein in step (ii), the solvent used for the purification of anhydrous Lapatinib ditosylate of formula (1) is tetrahydrofuran.
8. A process for the preparation of anhydrous Lapatinib ditosylate (1) comprising the steps of:
a) reacting N-(3-chloro-4-(3-fluorobenzyloxy)anilino)-6-quinazolinyl)-furan-2- carbaldehyde(3) with 2-methanesulfonylethylamine HC1(7) in presence of triethylamine and solvent to get N-{3-chloro-4-[(fluorobenzyloxy] phenyl} -6- [5-({ [2-methanesulphonyl)ethyl]imino}methyl)-2-furyl]-4-quinazolinamine(8), b) reducing the N-{3-chloro-4-[(fluorobenzyloxy]phenyl}-6-[5-({ [2-methane- sulphonyl)ethyl]imino}methyl)-2-furyl]-4-quinazolinamine (8) with sodium borohydride in presence of dichlorome thane -methanol mixture to obtain Lapatinib free base (2),
c) crystalizing the Lapatinib base from isopropanol to get pure Lapatinib base (2), d) reacting Lapatinib base of formula-(2) by dissolving or suspending in tetrahydrofuran/water medium with p-toluenesulfonic acid monohydrate to obtain anhydrous Lapatinib ditosylate of formula-(l).
e) Optionally purifying the anhydrous Lapatinib ditosylate of formula (1) is purified using organic solvent.
9. The process according to claim 8, wherein in step-a) the solvent is selected from dichlorome thane, dichloroe thane and chlorobenzene.
10. The process according to claim 8, wherein the solvent used for the purification of anhydrous Lapatinib ditosylate of formula (1) is tetrahydrofuran.
PCT/IN2019/050930 2018-12-27 2019-12-17 Improved process for the preparation of lapatinib base and it's anhydrous ditosylate salt WO2020136671A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201841049252 2018-12-27
IN201841049252 2018-12-27

Publications (1)

Publication Number Publication Date
WO2020136671A1 true WO2020136671A1 (en) 2020-07-02

Family

ID=71128554

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2019/050930 WO2020136671A1 (en) 2018-12-27 2019-12-17 Improved process for the preparation of lapatinib base and it's anhydrous ditosylate salt

Country Status (1)

Country Link
WO (1) WO2020136671A1 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120245351A1 (en) * 2009-09-29 2012-09-27 Natco Pharma Limited Process for the preparation of lapatinib and its pharmaceutically acceptable salts
US8530701B2 (en) * 2007-12-11 2013-09-10 Newron Pharmaceuticals, S.P.A. High purity 2-[4-(3- OR 2-fluorobenzyloxy)benzylamino]propanamides and methods of use thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8530701B2 (en) * 2007-12-11 2013-09-10 Newron Pharmaceuticals, S.P.A. High purity 2-[4-(3- OR 2-fluorobenzyloxy)benzylamino]propanamides and methods of use thereof
US20120245351A1 (en) * 2009-09-29 2012-09-27 Natco Pharma Limited Process for the preparation of lapatinib and its pharmaceutically acceptable salts

Similar Documents

Publication Publication Date Title
US8664389B2 (en) Process for the preparation of lapatinib and it's pharmaceutically acceptable salts
EP2139868B1 (en) Process for preparation of erlotinib and its pharmaceutically acceptable salts
US7799916B2 (en) Process for the preparation of 5-(4-[4-(5-cyano-3-indolyl)butyl]-1-piperazinyl)benzofuran-2-carboxamide
US8481730B2 (en) Method of synthesis of Bosentan, its polymorphic forms and its salts
CN108864050B (en) Method for synthesizing Arotinib and hydrochloride thereof
CN104945332B (en) The preparation method of Erlotinib
US10377712B2 (en) Process for preparation of apremilast and novel polymorphs thereof
US10266507B2 (en) Process for the preparation of ranolazine
JPWO2006064945A1 (en) Method for producing muscarinic receptor antagonist and intermediate thereof
WO2021214785A1 (en) Improved process for the preparation of roxadustat
WO2022088573A1 (en) Method for preparing pyrotinib
WO2014180271A1 (en) Method for preparing afatinib and intermediate thereof
EP2655364A1 (en) A process for the preparation of lapatinib and its ditosylate salt
WO2020136671A1 (en) Improved process for the preparation of lapatinib base and it's anhydrous ditosylate salt
CN112979552A (en) Preparation method of high-purity dexmedetomidine hydrochloride
WO2019174101A1 (en) Method for preparing tenofovir
US8093384B2 (en) Processes for the preparation of alfuzosin
JP2015038053A (en) Method for producing 4-(2-methyl-1-imidazolyl)-2,2-phenylbutane amide
CN112979553A (en) Synthesis method of dexmedetomidine
EP2277866A1 (en) Process for preparing telmisartan
JP4790901B2 (en) Process for producing 4-amino-5-cyanoimidazole derivative and its intermediate
CN115850240B (en) Synthesis method of medicine ao Lu Taxi Ni for treating acute myelogenous leukemia
US8569322B2 (en) Lamivudine oxalate and preparation method thereof
CN110885315A (en) Preparation method of important intermediate of levosimendan
CN113493423A (en) Method for synthesizing key intermediate of immunomodulator

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19903348

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19903348

Country of ref document: EP

Kind code of ref document: A1